BAVA: Bavarian Nordic A/S - Summary | Jitta

Bavarian Nordic A/S

DNK:BAVA

Price
kr189.40
Loss Chance
47.1%
3.60JITTA SCORE
8.24%Over Jitta Line
Jitta Ranking
80 / 124
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (28)
Recent Business Performance (42)
Financial Strength (85)
Return to Shareholders (17)
Competitive Advantage (44)
Jitta Signs
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 128.00% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
3.60
8.24%
4.31
19.78%
4.95
38.73%
Biotechnology
2.91
100.00%
6.10
30.14%
n/a
100.00%
COMPANY DESCRIPTION
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.